HSCs are found in the bone marrow of adults, which includes femurs, hip, ribs, sternum, and other bones. Cells can be obtained directly by removal from the hip using a needle and syringe, or from the blood following pre-treatment with cytokines, such as G-CSF (granulocyte colony-stimulating factors), that induce cells to be released from the bone marrow compartment. Other sources for clinical and scientific use include umbilical cord blood, placenta, mobilized peripheral blood. For experimental purposes, fetal liver, fetal spleen, and AGM (Aorta-gonad-mesonephros) of animals are also useful sources of HSCs.
It is known that a small number of HSCs can expand to generate a very large number of progeny HSCs. This phenomenon is used in bone marrow transplant when a small number of HSCs reconstitute the hematopoietic system. This indicates that, at least during bone marrow transplant, symmetrical cell divisions that give two progeny HSCs must occur, as expansion in HSC numbers seen during bone marrow transplant cannot occur in any other way.
Stem cell self-renewal is thought to occur in the stem cell niche in the bone marrow, and it is reasonable to assume that key signals present in this niche will be important in self-renewal. There is much interest in the environmental and molecular requirements for HSC self-renewal, as understanding the ability of HSC to replenish themselves will eventually allow the generation of expanded populations of HSC ex vivo that can be used therapeutically.
This ability is the reason why HSCs may be harvested directly from the blood.
However, not all stem cells are covered by these combinations that nonetheless have become popular. In fact, even in humans, there are hematopoietic stem cells that are CD34-/CD38-. . Also some later studies suggested that earliest stem cells may lack c-kit on the cell surface. For human HSCs use of CD133 was one step ahead as both CD34+ and CD34- HSCs were CD133+.
Traditional purification method used to yield a reasonable purity level of mouse hematopoietic stem cells, in general, requires a large(~10-12) battery of markers, most of which were surrogate markers with little functional significance, and thus partial overlap with the stem cell populations and sometimes other closely-related cells that are not stem cells. Also, some of these markers 9eg Thy1) are not conserved across mouse species, and use of markers like CD34- for HSC purification requires mice to be at least 8 weeks old. Alternative methods that could give rise to similar or better harvest of stem cells is a hot area of research and are presently emerging. One such method uses a signature of SLAM family of cell surface molecules. SLAM (Signaling lymphocyte activation molecule) family is a group of >10 molecules whose genes are mostly located tandemly in a single locus on chromosome 1 (mouse), all belonging to a subset of immunoglobulin gene superfamily, and originally thought to be involved in T-cell stimulation. This family includes CD48, CD150, CD244, etc., CD150 being the founding member, and, thus, also called slamF1 ie SLAM family member 1.
The signature SLAM code for the hemapoietic higherchy are:
For HSCs, CD150+CD48- was sufficient instead of CD150+CD48-CD244- because CD48 is a ligand for CD244, and both would be positive only in the activated lineage-restricted progenitors. It seems that this code was more efficient than the more tedious earlier set of the large number of markers, and are also conserved across the mouse strains; however, recent work has shown that this method excludes a large number of HSCs and includes an equally large number of non-stem cells.. CD150+CD48- gave stem cell purity comparable to Thy1loSca-1+lin-c-kit+ in mice.
Irving Weissman's group at Stanford University that was the first to isolate mouse hematopoietic stem cells in 1988, was also the first to work out the markers to distinguish the mouse long-term (LT-HSC) and short-term (ST-HSC) hematopoietic stem cells (self-renew-capable), and the Multipotent progenitors (MPP, low or no self-renew capability — the later the developmental stage of MPP, the lesser the self-renewal ability and the more of some of the markers like CD4 and CD135):
The root for CFU-E is "rubri", for CFU-GM is "granulo" or "myelo" and "mono", for CFU-L is "lympho" and for CFU-Me is "megakaryo". According to this terminology, the stages of red blood cell formation would be: rubriblast, prorubricyte, rubricyte, metarubricyte, and erythrocyte. However, the following nomenclature seems to be, at present, the most prevalent:
|Committee||"lympho"||"rubri"||"granulo" or "myelo"||"mono"||"megakaryo"|
|meta[root]cyte||Large lymphocyte||Reticulocyte||Eosinophilic/neutrophilic/basophilic metamyelocyte, Eosinophilic/neutrophilic/basophilic band cell||Early monocyte||-|
|mature cell name||Small lymphocyte||Erythrocyte||granulocytes (Eosino/neutro/basophil)||Monocyte||thrombocytes (Platelets)|
Osteoclasts also arise from haemopoietic cells of the monocyte/neutrophil lineage, specifically CFU-GM.
The above CFUs are based on the lineage. Another CFU, the colony-forming unit–spleen (CFU–S) was the basis of an in vivo clonal colony formation, which depends on the ability of infused bone marrow cells to give rise to clones of maturing hematopoietic cells in the spleens of irradiated mice after 8 to 12 days. It was used extensively in early studies, but is now considered to measure more mature progenitor or Transit Amplifying Cells rather than stem cells.
Stem cells are generally defined as those cells in any living system that have two properties: A. Pluri-potency, i.e. the ability to differentiate into a tissue of mature uni-potent cells; B. Self-renewal capacity, i.e. the ability to maintain their own population at an approximately constant level.The most basic stem cell in higher animals is the embryonic stem cell which gives rise to other tissue stem cells such as neuronal, mesenchymal, or hematopoietic stem cells. The latter are the stem cells which generate and maintain the blood system.
Hematopoietic stem cells (HSC), like other stem cells, can not be observed directly or be isolated due to an uncertainty relationship based on the incomensurability of properties A and B above. Rather, HSC behaviors need to be inferred through indirect strategies based on the logic "If a tissue transplant yields a full hematopoietic system in an ablated host, then there was at least one HSC in the donor transplant". Sophisticated experimental methods exist to ascertain that, with a high probability, a very small number of HSC (1-2) is contained in a transplant. Therefore, it is possible to measure the number of donor-derived cells in the host over time as properties A and B are iterated in the process referred to as reconstitution.
These reconstitution kinetics are very heterogeneous. Surprisingly, using symbolic dynamics, one can show that they fall into a limited number of classes. It is assumed that the hematopoietic dynamical system has three states ("+" for increased repopulation activity, "-" for decreased repopulation activity, and "~" for experimentally undetectable repopulation activity between successive measurements of the number of donor-derived cells). As the state changes are followed over at least 7 and up to 48 months, a specific sequence of symbols can be associated with each reconstitution event. Using the Hamming distance on these sequences shows then that they fall into a limited number of kinetic clusters according to a truncated power-law distribution of the form F(r) = γ r-(1/d) e-(1/λ)r between the frequency and the rank of a symbolic kinetic. This allows several conclusions. The HSC compartment is heterogeneous - there is no mother-of-all hematopoietic stem cell. Epigenetic imprinting may play an essential role in the generation of diversity of the blood system. Finally, the probability of occurrence of new patterns is very small and, thus, the above classification describes the full repertoire of HSC. Therefore, analyzing the hematopoietic system as a discrete dynamical system has played an essential role in understanding its origins which, in turn, provides valuable clues for discovering new approaches for therapeutic intervention.